

1. [‘Awareness about IPR needed’](#) –**The Times of India**

Stressing on the growing need of Intellectual Property Rights (IPR), senior advocate Saresh Lotlikar urged people to acquaint themselves with the rising number of litigations on IPR issues pending in Indian courts.

"IPR is gaining a lot of relevance at the global level and Delhi, comparatively, has the highest number of litigations pending on IPR issues. Further, petitions on copyright are also filed before the high court of Bombay at Goa and, in order to avoid confusion regarding IPR violations, all should be aware of the law in force," he said while addressing the audience a seminar on IPR last week.

2. [Are you sure the medicine you are consuming is at the right price?](#) – Business Today

Although there are norms and punishments for overcharging for medicines, but it is not a good idea for a consumer to just depend on the pharmaceutical companies or the pharmacies to get the correct price prescribed by the government as effective monitoring system is absent. For

instance, the government had brought 103 medicines under price control regime with new MRP (maximum retail price) effective from April 1, 2016, but there are still instances of consumers complaints about drugs being sold at the old MRP - a good five months after the new list was released.

The note accompanying the list clearly states that "the manufacturer not complying with the (new) ceiling price shall be liable to deposit the overcharged amount along with the interest." While most companies seem to be following the norms, but there are still many complaints about old MRP medicines.

3. [Code for pharma firms to have more teeth](#) – The Economic Times

The promised mandatory marketing code for pharma companies, which is to replace the voluntary code in operation since January last year, will have strong penal provisions to deter them from bribing doctors with freebies to prescribe their drugs. The voluntary code, initially

1. [‘Awareness about IPR needed’](#) – The Times of India
2. [Are you sure the medicine you are consuming is at the right price?](#) – Business Today
3. [Code for pharma firms to have more teeth](#) – The Economic Times
4. [Medical device parks to bring down manufacturing cost by 30%](#) - Business Standard
5. [South-East Asian countries pledge against non-communicable diseases](#) – The Indian Express
6. [Health Ministry launches the biggest Leprosy Case Detection Campaign in the country 32 crore persons to be screened across 19 States/UTs](#) – Business Standard
7. [Glenmark announces discovery and initiation of clinical development of novel anti-cancer drug](#) – Mint
8. [Dr Reddy’s Foundation launches placement-linked skill development program](#) – The Hindu Business Line
9. [Sun Pharma inks distribution pact with Mitsubishi Tanabe](#) – The Hindu Business Line
10. [Lupin receives USFDA nod for anti-bacterial tablets](#) – The Hindu
11. [Substandard drugs in Indian domestic market comes down to 4.5% from 8%](#) - Pharmabiz.com
12. [Pharmasafe India to be held in Mumbai from September 22 to 23](#) – Pharmabiz.com

applicable till June 2015, has been given four extensions despite the department repeatedly admitting it wasn't working. A senior official in the chemicals and fertilisers ministry explained that the delay in the mandatory code was because, instead of merely converting the toothless voluntary code to a mandatory one, the ministry was reworking it to ensure it included penal provisions.

4. [**Medical device parks to bring down manufacturing cost by 30% - Business Standard**](#)
Through medical devices parks, the government aims to increase competitiveness of the Indian industry globally by helping it to bring down the manufacturing cost significantly. "Setting up of these parks can bring down the manufacturing cost by another 30 per cent and make Indian medical technology sector globally competitive, due to pooling of common facilities," said Ananth Kumar, Minister for Chemicals & Fertilizers and Parliamentary Affairs, at the medical technology conference in New Delhi recently. The first medical technology park has already been set up in Vishakhapatnam, Andhra Pradesh, with an investment of Rs 1200 crore. Himachal Pradesh, Gujarat, Telangana and Maharashtra have also shown interest in setting up such parks.
5. [**South-East Asian countries pledge against non-communicable diseases – The Indian Express**](#)
South-East Asian countries recently adopted 'Colombo declaration' to manage the growing epidemic of non-communicable diseases that kill 8.5 million people annually. The declaration calls for strengthening delivery of services for these diseases at the primary health care level. As part of the declaration health ministers pledged to undertake targeted screening for early diagnosis, as well as to increase health guidance and counselling to promote healthy choices and self-care. Ensuring appropriate treatment, robust follow-up, management of referrals and focusing on and expanding NCD services to the high-risk population are key parts of the declaration.
6. [**Health Ministry launches the biggest Leprosy Case Detection Campaign in the country 32 crore persons to be screened across 19 States/UTs – Business Standard**](#)
In line with the vision of Shri Narendra Modi, Honble Prime Minister of India to eradicate Leprosy from India, Shri J P Nadda, Union Minister of Health and Family Welfare reviewed the National Leprosy Eradication Programme and pursuant to that, Ministry Of Health And Family Welfare has launched the biggest Leprosy Case Detection Campaign (LCDC) in the country on 5th September 2016 across 149 districts of 19 states/UTs. This fortnight-long campaign will cover 1656 blocks/urban areas of these districts and screen a total of 32 crore people for leprosy. For this purpose, 297604 teams comprising of one lady ASHA worker and one male volunteer each would visit every house in their allotted area and screen all the family members for leprosy.
7. [**Glenmark announces discovery and initiation of clinical development of novel anti-cancer drug – Mint**](#)
Glenmark Pharmaceuticals Ltd on Tuesday said it has discovered a novel drug candidate for the treatment of cancer and plans to conduct clinical trials. The experimental drug, GBR 1372, kills cancer cells by redirecting immune response to destroy cancer cells. "Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd, has announced the discovery and initiation of IND (investigational new drug) enabling studies for a novel bispecific monoclonal antibody, GBR 1372, targeting EGFR (epidermal growth factor receptor)," said the company in a statement.

Also reported by-
 - [**Glenmark initiates IND-enabling studies targeting cancer**](#) – The Financial Express
 - [**Glenmark's Expands Oncology Portfolio With New Discovery**](#) – Bloomberg Quint
8. [**Dr Reddy's Foundation launches placement-linked skill development program – The Hindu Business Line**](#)
Dr Reddy's Foundation, part of the Hyderabad-based Pharma major Dr Reddy's Laboratories has launched a skill gap bridging effort for the youth, including those with disabilities called GROW. GROW, emerges out of the Foundation's experience and research to match present and future

market needs for skilled workers. It will address the complex problem of youth unemployment through a placement-linked skill development program. It will be a natural corollary to the Livelihood Advancement Business School (LABS), launched in 2000

9. [Sun Pharma inks distribution pact with Mitsubishi Tanabe](#) – The Hindu Business Line

Drug major Sun Pharma has announced initiation of a phased transfer of manufacturing and marketing rights of 14 brands, it acquired from Swiss drug firm Novartis in Japan, earlier this year for \$293 million. “These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma’s subsidiary in Japan beginning October 2016,” Sun Pharma said in a statement today. The company said it has signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation for these 14 prescription brands.

Also reported by-

- [Sun Pharma strikes distribution alliance with Mitsubishi Tanabe in Japan](#) – The Economic Times
- [Sun Pharma ropes in Mitsubishi Tanabe to distribute products in Japan](#) – Business Standard
- [Sun Pharma partners Mitsubishi Tanabe to sell 14 prescription brands in Japan](#) – Mint

10. [Lupin receives USFDA nod for anti-bacterial tablets](#) – The Hindu

Lupin’s U.S. subsidiary, Gavis Pharmaceuticals LLC, USA, has received tentative approval for its Moxifloxacin Hydrochloride Tablets, 400 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Bayer Healthcare Pharmaceuticals Inc.’s Avelox Tablets, 400 mg in the US, Lupin said in a statement. Avelox had U.S. sales of \$ 30.1 million. Meanwhile, Lupin has received tentative approval for its Silodosin Capsules, 4 mg and 8 mg from the USFDA to market a generic version of Allergan Sales, LLC's RapafloCapsules, 4 mg and 8 mg. Rapaflo had US sales of \$228.7 million. — Special Correspondent

Also reported by-

- [Lupin gains after tentative USFDA nod for generic drug](#) – Business Standard
- [Lupin gets tentative nod from USFDA for Silodosin capsules](#) – The Hindu Business Line

11. [Substandard drugs in Indian domestic market comes down to 4.5% from 8%](#) - Pharmabiz.com

Trends on sub-standard drugs based on a nation-wide study coupled with routine random-sampling exercises done over a period of one year reveals that presence of sub-standard drugs in India has considerably come down from 8 per cent to 4.5 per cent. Routine sampling and tests of drugs by Central Drug Standards Control Organization (CDSCO) usually check the quality of drugs using parameters like dissolution and assay. The decrease in trend has been the key highlight of a risk-based assessment done in the country based on a statistically designed system which shows similar trends existing globally in terms of circulation of sub-standard drugs in India. Sub-standard drugs in India are no exception if compared to the trends internationally in regulated and developed markets.

12. [Pharmasafe India to be held in Mumbai from September 22 to 23](#) – Pharmabiz.com

Following the success of the launch edition of Pharmasafe India last year, the two-day conference will take place from September 22 – 23, 2016 at Holiday Inn, Mumbai. Messe Frankfurt Trade Fairs India Pvt Ltd continues its commitment to fighting the menace of counterfeit and spurious drugs and will draw attention to the latest developments in the field at the much-awaited second edition.

A Following a special keynote address on Streamlining Anti-Counterfeiting Regulations in 2016, high-profile speakers including **Dr. Shailesh Ayyangar, managing director, India & vice president, South Asia, Sanofi & president, Organization of Pharmaceutical Producers of India (OPPI)**. Apart from an eminent speaker panel, the conference has also drawn support from both pharmaceutical companies and industry associations such as **OPPI**, IDMA, IPA, IPEC, ASPA, Sanofi and HP.